We’ve been partnering with UNICEF INNOVATION to launch new e-commerce services for rural markets, expanding access to affordable health & financial products worldwide
A little over six months ago, five startups based and working in the Philippines were onboarded into ING and UNICEF’s first ever Fintech for Impact cohort.
These companies were chosen through a competitive process for this opportunity because they are building innovative open source solutions with potential to provide families and youth in the Philippines with better financial stability and opportunity.
In addition to investment, the cohort has also received individualized support from UNICEF mentors to strengthen their business strategies – as well as in how to “work in the open” – how to set up, grow, license and sustain their open source technology or content solutions. They have also met with experts at ING, which is providing access to the core business skills of their staff to support the growth of the startups.
In addition, Manila-based startup accelerator IdeaSpace is providing wrap-around support to the cohort, to monitor progress, needs, and challenges – and match the startups with the many mentors and resources they have available in their network.
Working throughout the pandemic and shifting lockdowns, as well as facing numerous weather events, the startups have had to find new ways of working and engaging with users on the ground, while accelerating the development of their solutions given the clearer need and urgency for social protection and financial stability.
Despite the pandemic, reach52 experienced our most impactful year to-date in 2021. Read our impact report for more on our tech developments, growing global presence and campaign spotlights.
Co-authored by reach52’s John Paluyo, reach52 alumni Rich Bryson and Medtronic Labs’ Anne Stake.
ជម្ងឺមិនឆ្លងបានធ្វើការយាយីជាបន្តបន្ទាប់ ដែលបណ្តាលឲ្យមានករណីស្លាប់នៅទូទាំងសកលលោក, ក្នុងចំណោមមនុស្ស ៥ នាក់មានមនុស្សចំនួន ៤ នាក់ដែលផ្ទុកជម្ងឹមិនឆ្លងរស់នៅក្នុងប្រទេសដែលមានប្រាក់ចំណូលទាប និងមធ្យម។ ទោះបីជាយ៉ាងណាក៏ដោយក៏ការធ្វើរោគវិនិច្ឆ័យរកជម្ងឺមិនឆ្លងនៅតែមានតម្លៃថ្លៃសម្រាប់កន្លែងថែទាំជម្ងឺកម្រិតបឋមនៅតាមតំបន់ដាច់ស្រយ៉ាល, ដែលវាបានធ្វើឲ្យមានការថែទាំខ្សោយបំផុតនៅក្នុងប្រព័ន្ធ។ ការបង្កើតថ្មីនៃការធ្វើរោគវិនិច្ឆ័យនឹងធ្វើឲ្យបានទៅដល់ប្រជាជនទាំងនោះក្នុងតម្លៃសមរម្យ។